KR102066845B1 - Plasma-treated pepper leaf extreact with improved anti-inflammatory effect and manufacturing method thereof - Google Patents
Plasma-treated pepper leaf extreact with improved anti-inflammatory effect and manufacturing method thereof Download PDFInfo
- Publication number
- KR102066845B1 KR102066845B1 KR1020180007220A KR20180007220A KR102066845B1 KR 102066845 B1 KR102066845 B1 KR 102066845B1 KR 1020180007220 A KR1020180007220 A KR 1020180007220A KR 20180007220 A KR20180007220 A KR 20180007220A KR 102066845 B1 KR102066845 B1 KR 102066845B1
- Authority
- KR
- South Korea
- Prior art keywords
- pepper leaf
- leaf extract
- plasma
- minutes
- present
- Prior art date
Links
- 235000002566 Capsicum Nutrition 0.000 title claims abstract description 51
- 239000006002 Pepper Substances 0.000 title claims abstract description 51
- 235000016761 Piper aduncum Nutrition 0.000 title claims abstract description 51
- 235000017804 Piper guineense Nutrition 0.000 title claims abstract description 51
- 235000008184 Piper nigrum Nutrition 0.000 title claims abstract description 51
- 238000004519 manufacturing process Methods 0.000 title abstract description 18
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract description 11
- 244000203593 Piper nigrum Species 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 61
- 241000722363 Piper Species 0.000 claims abstract description 50
- 239000000203 mixture Substances 0.000 claims abstract description 36
- 240000004160 Capsicum annuum Species 0.000 claims abstract description 22
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 claims abstract description 22
- 235000007862 Capsicum baccatum Nutrition 0.000 claims abstract description 22
- 239000001728 capsicum frutescens Substances 0.000 claims abstract description 22
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- 239000002537 cosmetic Substances 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 11
- 235000013376 functional food Nutrition 0.000 claims abstract description 10
- 230000036541 health Effects 0.000 claims abstract description 9
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 201000004624 Dermatitis Diseases 0.000 claims description 6
- 206010003246 arthritis Diseases 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 208000004232 Enteritis Diseases 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 206010029240 Neuritis Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 201000002661 Spondylitis Diseases 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 201000003146 cystitis Diseases 0.000 claims description 2
- 230000003412 degenerative effect Effects 0.000 claims description 2
- 208000007565 gingivitis Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 206010023332 keratitis Diseases 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 201000001245 periodontitis Diseases 0.000 claims description 2
- 206010034674 peritonitis Diseases 0.000 claims description 2
- 208000008423 pleurisy Diseases 0.000 claims description 2
- 206010039083 rhinitis Diseases 0.000 claims description 2
- 208000000143 urethritis Diseases 0.000 claims description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 abstract description 10
- 235000013824 polyphenols Nutrition 0.000 abstract description 10
- 238000009832 plasma treatment Methods 0.000 abstract description 8
- 230000003078 antioxidant effect Effects 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- -1 pH regulators Substances 0.000 description 14
- 238000009472 formulation Methods 0.000 description 11
- 239000002158 endotoxin Substances 0.000 description 8
- 229920006008 lipopolysaccharide Polymers 0.000 description 8
- 239000006071 cream Substances 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000002292 Radical scavenging effect Effects 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 3
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 3
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 3
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 3
- 229910052721 tungsten Inorganic materials 0.000 description 3
- 239000010937 tungsten Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 1
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- PQZSQOYXZGDGQW-UHFFFAOYSA-N [W].[Pb] Chemical compound [W].[Pb] PQZSQOYXZGDGQW-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- HOWJQLVNDUGZBI-UHFFFAOYSA-N butane;propane Chemical compound CCC.CCCC HOWJQLVNDUGZBI-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003848 cartilage regeneration Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000010891 electric arc Methods 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001165 hyssopus officinalis l. extract Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000019654 spicy taste Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/30—Physical treatment, e.g. electrical or magnetic means, wave energy or irradiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/12—Electrical treatment, e.g. electrolysis, electrical field treatment, with or without heating effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Birds (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 항염증 효과가 증진된 플라즈마 처리된 고춧잎 추출물 및 그의 제조방법에 관한 것으로, 플라즈마 처리된 고춧잎 추출물은 플라즈마를 처리하지 않은 고춧잎 추출물에 비해 총 폴리페놀 함량이 증가되고, 항산화 효과 및 NO 생성 억제효과가 현저히 증진되므로, 본 발명의 제조방법으로 제조된 고춧잎 추출물을 유효성분으로 함유하는 조성물은 염증성 질환의 치료제, 항염증용 건강기능식품 또는 기능성 화장품으로서 유용하게 사용할 수 있다.The present invention relates to a plasma-treated pepper leaf extract with an anti-inflammatory effect and a method for preparing the same, wherein the plasma-treated pepper leaf extract has an increased total polyphenol content, an antioxidant effect and NO production compared to the pepper leaf extract without plasma treatment. Since the inhibitory effect is remarkably enhanced, the composition containing the red pepper leaf extract prepared by the manufacturing method of the present invention as an active ingredient can be usefully used as a therapeutic agent for inflammatory diseases, an anti-inflammatory health functional food or a functional cosmetic.
Description
본 발명은 항염증 효과가 증진된 플라즈마 처리된 고춧잎 추출물 및 그의 제조방법에 관한 것이다. The present invention relates to a plasma-treated pepper leaf extract having an enhanced anti-inflammatory effect and a method for producing the same.
염증(inflammation)은 물리적인 상처나 미생물에 감염되었을 때 일어나는 정상적인 생체의 방어기전(defense mechanism)의 일종이며, 이 염증작용을 통하여 발병요인(pathogen)을 중화시키거나 제거하고, 손상된 조직을 복구시켜 정상적인 구조와 기능을 하게 한다. 염증을 동반하는 대부분의 질환은 조직의 손상, 통증 및 가려움증과 같은 삶의 질을 떨어뜨리는 결과를 초래하고, 만성적인 염증상태는 관절염, 천식, 뇌와 척수의 다발성 경화증, 염증성 장 질환 및 동맥 경화증을 일으킨다.Inflammation is a normal defense mechanism that occurs when a person is injured by a physical wound or microorganism. The inflammatory action neutralizes or eliminates pathogens and repairs damaged tissue. It has a normal structure and function. Most diseases with inflammation result in poor quality of life such as tissue damage, pain and itching, and chronic inflammatory conditions include arthritis, asthma, multiple sclerosis of the brain and spinal cord, inflammatory bowel disease, and atherosclerosis. Causes
대식세포는 선천면역을 담당하는 주요 세포로, 사이토카인 및 박테리아 지질다당류 내독소(lipopolysaccharide, LPS) 같은 수많은 인자에 의해 활성화되고, 활성화된 대식세포는 산화질소(nitric oxide, NO) 및 프로스타글란딘 E2(prostaglandin E2, PGE2) 같은 염증 인자는 물론 TNF-α(tumor necrosis factor-α), IL-6(interleukin-6), IL-1(interleukin-1) 같은 전염증성 사이토카인을 생산한다. NO는 자유 라디칼(free radical)의 일종으로 산화질소 합성효소(nitric oxide synthase, NOS)에 의해 합성되며, eNOS(endothelial NOS), nNOS(neuronal NOS) 및 iNOS(inducible NOS)의 3개의 동형 단백질(isoform)이 존재한다(Cho 등. 2014. Biomol. Ther. 22: 288-294). IL-1, TNF-α, 인터페론-감마(interferon-gamma) 같은 전염증성 사이토카인들은 iNOS 발현을 유발하고 NO 생산을 일으킬 수 있다. 뇌암, 유방암, 폐암, 전립선암, 췌장암 및 흑색종 같은 많은 악성 암들이 iNOS 발현과 연관되어 있고, 과도한 NO의 생산은 상피세포암, 돌연변이 및 DNA 구조 손상을 일으킬 수 있다.Macrophages are the main cells responsible for innate immunity, which are activated by numerous factors such as cytokines and bacterial lipopolysaccharide (LPS), and activated macrophages are nitric oxide (NO) and prostaglandin E 2 It produces proinflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1 (IL-1) as well as inflammatory factors such as prostaglandin E 2 and PGE 2 . NO is a free radical that is synthesized by nitric oxide synthase (NOS), and isomorphic protein (eNOS), three isoforms (neunoal NOS) and iNOS (inducible NOS). isoform) (Cho et al. 2014. Biomol. Ther. 22: 288-294). Proinflammatory cytokines such as IL-1, TNF-α and interferon-gamma can induce iNOS expression and cause NO production. Many malignant cancers such as brain cancer, breast cancer, lung cancer, prostate cancer, pancreatic cancer and melanoma are associated with iNOS expression, and excessive production of NO can cause epithelial cell cancer, mutations and DNA structure damage.
한편, 고춧잎은 수분 79.4%, 단백질 4.1%, 지질 1%, 섬유소 3.8%, 당질 8.2%, 회분 3.5%로 구성되어 있고, 풍부한 비타민 A, 비타민 C, 폴리페놀, 플라보노이드 등을 함유하고 있으며, DPPH 라디칼 소거능, 과산화수소 소거능 및 높은 항산화능을 가지고 있다는 것이 보고되었다. 또한, 유방암, 대장암 및 위암 등의 암세포 증식 억제효과, 보체계 활성효과 등 항암효과와 면역증진, 항균활성 및 티로시나아제(tyrosinase) 저해 활성 등을 가진다고 알려져 있다. 이러한 고춧잎의 어린순은 일부 식용으로 활용되고 있지만, 대부분의 고춧잎과 줄기 부위는 폐기되고 있다. 고춧잎은 고추 과육과 달리 매운맛이 없으면서 유용한 물질을 함유하고 있으므로 이를 활용한 기능성 소재의 개발시 고기능성의 고부가 제품을 개발할 수 있어 산업적 활용가치가 매우 높은 자원이다.On the other hand, red pepper leaves are composed of 79.4% moisture, 4.1% protein, 1% lipid, 3.8% fibrin, 8.2% sugar, and 3.5% ash, and contain abundant vitamin A, vitamin C, polyphenols, flavonoids, and DPPH. It has been reported to have radical scavenging activity, hydrogen peroxide scavenging activity and high antioxidant activity. In addition, it is known to have anticancer effects such as cancer cell proliferation inhibitory effect, complement system activation effect such as breast cancer, colorectal cancer and gastric cancer, immune enhancement, antibacterial activity and tyrosinase inhibitory activity. The young shoots of these pepper leaves are used for some food, but most of the pepper leaves and stems are discarded. Red pepper leaves, unlike red pepper flesh, do not have a spicy taste and contain useful substances, so they can develop high-value, high value-added products when developing functional materials using them.
한편, 전리된 가스 상태인 플라즈마에는 전자, 양이온, 음이온, 자유라디칼 및 광자 등을 포함하는 활성산소종이 존재한다. 그 중 열 플라즈마는 주로 아크 방전에 의해 발생시킨 전자, 이온, 중성입자로 구성된 기체로 구성입자가 1000~2000m/s를 갖는 고속의 제트 불꽃 형태를 이루고 있다. 이러한 고온, 고열용량, 고속, 다량의 활성입자를 갖는 열플라즈마의 특성을 이용하여 재래식 기술에서는 만들 수 없는 다양하고 효율적인 고온 열원이나 물리화학 반응자(reactor)로 사용되어, 여러 산업분야에서 이용되고 있다. On the other hand, active oxygen species including electrons, cations, anions, free radicals, photons and the like exist in the ionized gas plasma. Among them, the thermal plasma is a gas composed mainly of electrons, ions, and neutral particles generated by arc discharge, and forms a high-speed jet flame having a constituent particle of 1000 to 2000 m / s. By using the characteristics of thermal plasma having high temperature, high heat capacity, high speed, and a large amount of active particles, it is used as various and efficient high temperature heat sources or physicochemical reactors which cannot be produced by conventional technology, and is used in various industrial fields. .
따라서 본 발명은 플라즈마 처리를 통해 우수한 효능소재인 고춧잎 추출물의 활성물질에 의한 효과를 더욱 증진시키고자 하였다. Therefore, the present invention intends to further enhance the effect of the active material of the pepper leaf extract which is an excellent efficacy material through plasma treatment.
한편, 한국등록특허 제1062171호에는 연골재생 효과가 있는 글루코사민을 포함하고, 염증성 질환 및 통증에 효과적인 인삼, 고춧잎, 백작약, 감초, 우슬 추출물을 함유하는 관절염 치료용 조성물이 개시되어 있으나, 본 발명의 항염증 효과가 증진된 플라즈마 처리된 고춧잎 추출물 및 그의 제조방법에 관해 개시된 바 없다.On the other hand, Korean Patent No. 1062171 discloses a composition for treating arthritis, which includes glucosamine having a cartilage regeneration effect, and which contains ginseng, red pepper leaves, white medicinal herbs, licorice and hyssop extract, which are effective against inflammatory diseases and pain. Plasma-treated pepper leaf extract with enhanced anti-inflammatory effect and a method of preparing the same have not been disclosed.
본 발명은 상기와 같은 요구에 의해 도출된 것으로, 항염증 효과가 증진된 플라즈마 처리된 고춧잎 추출물 및 그의 제조방법을 제공하고, 상기 제조방법으로 제조된 플라즈마 처리된 고춧잎 추출물의 총 폴리페놀 함량이 증가하고, 항산화 및 항염효과를 나타내는 것을 확인함으로써, 본 발명을 완성하였다. According to the present invention, the present invention provides a plasma-treated pepper leaf extract and a method for preparing the same, and the total polyphenol content of the plasma-treated pepper leaf extract produced by the method is increased. The present invention was completed by confirming that the antioxidant and anti-inflammatory effects were exhibited.
상기 과제를 해결하기 위하여, 본 발명은 In order to solve the above problems, the present invention
1) 고춧잎 건조 분말에 용매를 첨가하여 고춧잎 추출물을 획득한 후 동결건조하는 단계; 및1) adding a solvent to the pepper leaf dry powder to obtain a pepper leaf extract and then lyophilized; And
2) 상기 단계 1)의 동결건조된 고춧잎 추출물 1 중량부에 대하여, 80~120 부피부의 물을 첨가한 후 플라즈마를 처리하는 단계;를 포함하는 항염효과가 증진된 고춧잎 추출물의 제조방법을 제공한다.2) to about 1 part by weight of the lyophilized red pepper leaf extract of step 1), adding 80 to 120 parts by volume of water and then treating the plasma; do.
또한, 본 발명은 상기 제조방법에 따라 제조된 항염효과가 증진된 고춧잎 추출물을 제공한다. In addition, the present invention provides a pepper leaf extract having an enhanced anti-inflammatory effect prepared according to the preparation method.
또한, 본 발명은 상기 고춧잎 추출물을 유효성분으로 함유하는 염증의 예방 또는 개선용 건강기능식품 조성물을 제공한다. In addition, the present invention provides a health functional food composition for the prevention or improvement of inflammation containing the pepper leaf extract as an active ingredient.
또한, 본 발명은 상기 고춧잎 추출물을 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학 조성물을 제공한다. The present invention also provides a pharmaceutical composition for the prevention or treatment of inflammatory diseases containing the pepper leaf extract as an active ingredient.
또한, 본 발명은 상기 고춧잎 추출물을 유효성분으로 함유하는 피부 염증의 예방 또는 개선용 화장료 조성물을 제공한다. The present invention also provides a cosmetic composition for the prevention or improvement of skin inflammation containing the red pepper leaf extract as an active ingredient.
본 발명의 제조방법으로 제조된 항염증 효과가 증진된 플라즈마 처리된 고춧잎 추출물은 플라즈마가 처리되지 않은 고춧잎 추출물에 비해 총 폴리페놀 함량이 증가하고, ABTS 및 DPPH 라디칼 소거능이 증가하였으며, LPS가 처리된 대식세포에서 NO의 생성을 억제하는 효과가 우수하였다. Plasma-treated red pepper leaf extract with enhanced anti-inflammatory effect prepared by the preparation method of the present invention was increased in total polyphenol content, increased ABTS and DPPH radical scavenging ability, and LPS-treated compared to red pepper leaf extract which was not treated with plasma. The effect of inhibiting NO production in macrophages was excellent.
도 1은 본 발명의 플라즈마 발생장치의 사진이다.
도 2는 본 발명의 제조방법으로 제조된 플라즈마 처리된 고춧잎 추출물의 세포독성을 확인한 결과이다. CON은 고춧잎 추출물을 처리하지 않은 음성대조군이다.
도 3은 본 발명의 제조방법으로 제조된 플라즈마 처리된 고춧잎 추출물의 NO 생성 억제효과를 확인한 결과이다. LPS를 처리하여 NO 생성을 유도하였다. CON은 고춧잎 추출물을 처리하지 않은 음성대조군이고, LPS는 LPS를 단독으로 처리하여 NO의 생성을 유도한 군이다. *, **은 플라즈마 처리 0분의 고춧잎 추출물 대비 NO의 생성량이 유의미하게 감소하였다는 것을 의미하며, *은 p<0.05, **은 p<0.01이다.1 is a photograph of a plasma generating apparatus of the present invention.
Figure 2 is a result confirming the cytotoxicity of the plasma-treated pepper leaf extract prepared by the manufacturing method of the present invention. CON is a negative control group not treated with pepper leaf extract.
3 is a result confirming the NO production inhibitory effect of the plasma-treated pepper leaf extract prepared by the production method of the present invention. LPS was treated to induce NO production. CON is a negative control group not treated with pepper leaf extract, LPS is a group inducing the production of NO by treating LPS alone. *, ** means that the amount of NO produced significantly decreased compared to the pepper leaf extract of 0 minutes plasma treatment, * is p <0.05, ** is p <0.01.
본 발명은 The present invention
1) 고춧잎 건조 분말에 용매를 첨가하여 고춧잎 추출물을 획득한 후 동결건조하는 단계; 및1) adding a solvent to the pepper leaf dry powder to obtain a pepper leaf extract and then lyophilized; And
2) 상기 단계 1)의 동결건조된 고춧잎 추출물 1 중량부에 대하여, 80~120 부피부의 물을 첨가한 후 플라즈마를 처리하는 단계;를 포함하는 항염효과가 증진된 고춧잎 추출물의 제조방법에 관한 것이다. 2) about 1 part by weight of the lyophilized red pepper leaf extract of step 1), adding 80 to 120 parts by volume of water and then treating the plasma; will be.
상기 단계 1)의 용매는 물, C1~C4의 저급 알코올 또는 이들의 혼합물인 것이 바람직하고, 더욱 바람직하게는 에탄올이지만, 이에 제한하지 않는다. The solvent of step 1) is preferably water, lower alcohols of C 1 ~ C 4 or mixtures thereof, more preferably ethanol, but is not limited thereto.
상기 단계 2)의 플라즈마 처리는 텅스턴 전극 사이에 사인파 펄스형 고전압을 가하여 생성된 플라즈마를 고춧잎 추출물에 처리하는 것이지만, 이에 제한되는 것은 아니다. Plasma treatment of step 2) is to process the plasma generated by applying a sinusoidal pulsed high voltage between the tungsten electrode to the pepper leaf extract, but is not limited thereto.
상기 고전압은 출력전압이 250~350V이고, 전류는 4~6A인 것이지만, 이에 한정하지 않는다.The high voltage has an output voltage of 250 to 350 V and a current of 4 to 6 A, but is not limited thereto.
상기 플라즈마 처리 시간은 100분~150분일 수 있으며, 바람직하게는 120분일 수 있으나, 이에 제한되지 않는다.The plasma treatment time may be 100 minutes to 150 minutes, preferably 120 minutes, but is not limited thereto.
본 발명의 플라즈마는 두 전극 사이에 전압을 걸어 전기장을 형성시킴으로써 전자파의 방전을 통해 발생시키는 저온 플라즈마이고, 대기압에서 플라즈마를 발생시키는 대기압 플라즈마이다. The plasma of the present invention is a low-temperature plasma generated through the discharge of electromagnetic waves by applying an electric voltage between two electrodes to form an electric field, and an atmospheric pressure plasma that generates plasma at atmospheric pressure.
본 발명의 바람직한 일 구현 예에서, In one preferred embodiment of the invention,
1) 고춧잎 건조 분말에 50~100%(v/v) 에탄올을 첨가하여 15~30℃의 온도에서 5~15시간 동안 추출하여 고춧잎 추출물을 획득한 후 여과하고, 여과된 여액을 동결건조하는 단계; 및1) adding 50 ~ 100% (v / v) ethanol to the pepper leaf dry powder for 5 to 15 hours to extract at a temperature of 15 ~ 30 ℃ to obtain a pepper leaf extract and filtered, and the filtered filtrate lyophilized ; And
2) 상기 단계 1)의 동결건조된 고춧잎 추출물 1g에 대하여 80~120㎖의 물을 첨가한 후 텅스턴 전극 사이에 사인파 펄스형 고전압을 가하여 생성된 플라즈마를 처리하는 단계;를 포함하여 항염효과가 증진된 고춧잎 추출물을 제조할 수 있으나, 이에 한정하는 것은 아니다.2) adding 80-120 ml of water to 1 g of the lyophilized red pepper leaf extract of step 1) and then applying a sinusoidal pulsed high voltage between the tungsten electrodes to process the generated plasma. Enhanced pepper leaf extract may be prepared, but is not limited thereto.
또한, 본 발명은 상기 제조방법에 따라 제조된 항염효과가 증진된 고춧잎 추출물에 관한 것이다. In addition, the present invention relates to a pepper leaf extract having an enhanced anti-inflammatory effect prepared according to the preparation method.
상기 고춧잎 추출물은 총 폴리페놀 함량이 일반 고춧잎 추출물에 비해 증가하고, 항산화 활성이 증진된다. The pepper leaf extract has a total polyphenol content is increased compared to the general pepper leaf extract, antioxidant activity is enhanced.
또한, 본 발명은 상기 고춧잎 추출물을 유효성분으로 함유하는 염증의 예방 또는 개선용 건강기능식품 조성물에 관한 것이다. The present invention also relates to a health functional food composition for preventing or improving inflammation containing the red pepper leaf extract as an active ingredient.
본 발명의 건강기능식품 조성물을 식품첨가물로 사용하는 경우, 상기 건강기능식품 조성물을 그대로 첨가하거나 다른 식품 또는 식품성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 양은 그의 사용 목적(예방 또는 개선)에 따라 적절하게 사용될 수 있다. 일반적으로, 식품 또는 음료의 제조시 본 발명의 건강기능식품 조성물은 원료에 대하여 15 중량부 이하, 바람직하게는 10 중량부 이하의 양으로 첨가된다. 그러나 건강을 목적으로 하는 장기간의 섭취인 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로 사용될 수 있다.When the health functional food composition of the present invention is used as a food additive, the health functional food composition may be added as it is or used with other foods or food ingredients, and may be appropriately used according to a conventional method. The amount of the active ingredient may be appropriately used depending on the purpose of use (prevention or improvement). In general, in the preparation of food or beverages, the nutraceutical composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less with respect to the raw material. However, in the case of long-term intake for health purposes, the amount may be below the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.
상기 건강기능식품의 종류에 특별한 제한은 없다. 상기 건강기능식품 조성물을 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There is no particular limitation on the type of dietary supplement. Examples of foods to which the health functional food composition may be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products, including ice cream, various soups, drinks, tea Drinks, alcoholic beverages, vitamin complexes, and the like, and include all health foods in the conventional sense.
또한, 본 발명의 건강기능식품 조성물은 식품, 특히 기능성 식품으로 제조될 수 있다. 본 발명의 기능성 식품은 식품 제조 시에 통상적으로 첨가되는 성분을 포함하며, 예를 들어, 단백질, 탄수화물, 지방, 영양소 및 조미제를 포함한다. 예컨대, 드링크제로 제조되는 경우에는 유효성분 이외에 천연 탄수화물 또는 향미제를 추가 성분으로서 포함할 수 있다. 상기 천연 탄수화물은 모노사카라이드(예컨대, 글루코오스, 프럭토오스 등), 디사카라이드(예컨대, 말토스, 수크로오스 등), 올리고당, 폴리사카라이드(예컨대, 덱스트린, 시클로덱스트린 등) 또는 당알코올(예컨대, 자일리톨, 소르비톨, 에리쓰리톨 등)인 것이 바람직하다. 상기 향미제는 천연 향미제(예컨대, 타우마틴, 스테비아 추출물 등)와 합성 향미제(예컨대, 사카린, 아스파르탐 등)를 이용할 수 있다.In addition, the nutraceutical composition of the present invention may be prepared as a food, in particular a functional food. Functional foods of the present invention include ingredients that are commonly added in food production, and include, for example, proteins, carbohydrates, fats, nutrients and seasonings. For example, when prepared with a drink, natural carbohydrates or flavoring agents may be included as additional ingredients in addition to the active ingredient. The natural carbohydrates can be monosaccharides (e.g. glucose, fructose, etc.), disaccharides (e.g. maltose, sucrose, etc.), oligosaccharides, polysaccharides (e.g. dextrins, cyclodextrins, etc.) or sugar alcohols (e.g. , Xylitol, sorbitol, erythritol and the like). The flavourant may be a natural flavourant (eg, taumartin, stevia extract, etc.) and a synthetic flavourant (eg, saccharin, aspartame, etc.).
상기 건강기능식품 조성물 이외에 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 더 함유할 수 있다. 이러한 상기 첨가되는 성분의 비율은 크게 중요하진 않지만 본 발명의 건강기능식품 조성물 100 중량부에 대하여, 0.01 내지 0.1 중량부의 범위에서 선택되는 것이 일반적이다.Various nutritional supplements, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohols, carbonic acid The carbonation agent etc. which are used for a drink can be contained further. Although the ratio of the above-mentioned ingredients is not critical, it is generally selected from 0.01 to 0.1 parts by weight based on 100 parts by weight of the health functional food composition of the present invention.
또한, 본 발명은 상기 고춧잎 추출물을 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학 조성물에 관한 것이다. The present invention also relates to a pharmaceutical composition for the prevention or treatment of inflammatory diseases containing the pepper leaf extract as an active ingredient.
본 발명에서 염증성 질환이란 관절염, 비염, 간염, 각막염, 위염, 장염, 신장염, 기관지염, 흉막염, 복막염, 척추염, 췌장염, 요도염, 방광염, 화상 염증, 피부염, 치주염, 치은염 및 퇴행성 신경 염증 중에서 선택된 하나 이상인 것을 의미한다. Inflammatory disease in the present invention is at least one selected from arthritis, rhinitis, hepatitis, keratitis, gastritis, enteritis, nephritis, bronchitis, pleurisy, peritonitis, spondylitis, pancreatitis, urethritis, cystitis, burn inflammation, dermatitis, periodontitis, gingivitis and degenerative nerve inflammation Means that.
본 발명의 약학조성물은 유효성분 이외에 약학적으로 허용되는 담체를 포함할 수 있으며, 이러한 담체는 제제 시에 통상적으로 이용되는 것으로서, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 아카시아 고무, 인산 칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세결정성 셀룰로스, 폴리비닐피롤리돈, 셀룰로스, 물, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함하나, 이에 한정되는 것은 아니다. 본 발명의 약학적 조성물은 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다. The pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier in addition to the active ingredient, and such carriers are commonly used in the preparation of lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, Calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and minerals Oils and the like, but are not limited thereto. In addition to the above components, the pharmaceutical composition of the present invention may further include a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, and the like.
본 발명에 따른 약학조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하게 처방될 수 있다. Suitable dosages of the pharmaceutical compositions according to the present invention may be variously prescribed by such factors as the formulation method, mode of administration, age, weight, sex, morbidity, food, time of administration, route of administration, rate of excretion and response to the patient. Can be.
본 발명의 약학조성물은 경구 또는 비경구로 투여할 수 있으며, 비경구 투여의 경우, 피부에 국소적으로 도포, 정맥 내 주입, 피하 주입, 근육 주입, 복강 주입, 경피 투여 등으로 투여할 수 있다. The pharmaceutical composition of the present invention can be administered orally or parenterally, and in the case of parenteral administration, it can be administered topically to the skin, intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration and the like.
본 발명의 조성물에 포함되는 유효성분의 농도는 치료 목적, 환자의 상태, 필요기간 등을 고려하여 결정할 수 있으며, 특정 범위의 농도로 한정되지 않는다.The concentration of the active ingredient included in the composition of the present invention can be determined in consideration of the purpose of treatment, the condition of the patient, the period of time, etc., and is not limited to a specific range of concentration.
본 발명의 약학조성물은 당해 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약학적으로 허용되는 담체 또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때 제형은 주사제, 크림, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 및 카타플라스마제 중에서 선택된 어느 하나의 제형으로 제조될 수도 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.The pharmaceutical compositions of the present invention may be prepared in unit dosage form by formulating with a pharmaceutically acceptable carrier or excipient according to methods which can be easily carried out by those skilled in the art. It can be prepared by incorporation into a dose container. In this case, the formulation may be prepared in any one formulation selected from injections, creams, patches, sprays, ointments, warnings, lotions, linings, pastas, and cataplasmas, and may further include dispersants or stabilizers. have.
또한, 본 발명은 상기 고춧잎 추출물을 유효성분으로 함유하는 피부 염증의 예방 또는 개선용 화장료 조성물에 관한 것이다. The present invention also relates to a cosmetic composition for preventing or improving skin inflammation containing the red pepper leaf extract as an active ingredient.
본 발명의 일 구현 예에 따른 화장료 조성물에 있어서, 상기 피부 염증용 화장료 조성물은 스킨, 스킨 소프트너, 스킨 토너, 로션, 밀크로션, 모이스쳐로션, 영양로션, 마사지크림, 영양크림, 아이크림, 모이스쳐크림, 핸드크림, 에센스, 영양에센스, 팩, 클렌징폼, 클렌징워터, 클렌징크림, 바디로션, 바디클렌져, 비누 및 파우더 중에서 선택된 어느 하나의 제형을 가질 수 있으나, 이에 제한되지 않는다. 이들 각 제형으로 이루어진 화장료 조성물은 그 제형의 제제화에 필요하고 적절한 각종의 기제와 첨가물을 함유할 수 있으며, 이들 성분의 종류와 양은 당업자에 의해 용이하게 선정될 수 있다. In the cosmetic composition according to an embodiment of the present invention, the skin inflammation cosmetic composition is a skin, skin softener, skin toner, lotion, milk lotion, moisturizing lotion, nutrition lotion, massage cream, nutrition cream, eye cream, moisturizer Cream, hand cream, essence, nutrition essence, pack, cleansing foam, cleansing water, cleansing cream, body lotion, body cleanser, soap and powder may have any one selected from, but is not limited thereto. The cosmetic composition consisting of each of these formulations may contain various bases and additives necessary for the formulation of the formulation and are suitable, and the type and amount of these components can be easily selected by those skilled in the art.
본 발명의 화장료 조성물의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물섬유, 식물섬유, 왁스, 파라핀, 전분, 트라가칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is a paste, cream or gel, the carrier component is animal fiber, vegetable fiber, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide. And the like can be used.
본 발명의 화장료 조성물의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판-부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the cosmetic composition of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as the carrier component, and in particular, in the case of a spray, additionally chlorofluorohydro Propellants such as carbon, propane-butane or dimethyl ether.
본 발명의 화장료 조성물의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용매화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the cosmetic composition of the present invention is a solution or emulsion, a solvent, solvating agent or emulsifying agent is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene Fatty acid esters of glycol, 1,3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
본 발명의 화장료 조성물의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is a suspension, as a carrier component, water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Microcrystalline cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
본 발명의 화장료 조성물의 제형이 계면-활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르설페이트, 설포숙신산 모노에스테르, 아세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 리놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is a surfactant-containing cleansing agent, as a carrier component, an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, acethionate, an imidazolinium derivative, methyl taurate, and sarcosinate Fatty acid amide ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
본 발명의 화장료 조성물은 형광물질, 살진균제, 굴수성 유발물질, 보습제, 방향제, 방향제 담체, 단백질, 용해화제, 당 유도체, 일광차단제, 비타민, 식물 추출물 등을 포함하는 부형제를 추가로 함유할 수 있다.The cosmetic composition of the present invention may further contain an excipient including a fluorescent substance, a fungicide, a caustic agent, a moisturizer, a fragrance, a fragrance carrier, a protein, a solubilizer, a sugar derivative, a sunscreen agent, a vitamin, a plant extract, and the like. .
이하, 제조예 및 실시예를 이용하여 본 발명을 더욱 상세하게 설명하고자 한다. 이들 제조예 및 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로 본 발명의 범위가 이들에 의해 제한되지 않는다는 것은 당해 기술분야에서 통상의 지식을 가진 자에게 있어 자명한 것이다. Hereinafter, the present invention will be described in more detail with reference to Preparation Examples and Examples. These preparations and examples are only intended to explain the present invention more specifically, it will be apparent to those skilled in the art that the scope of the present invention is not limited thereto.
제조예Production Example 1. One. 플라즈마plasma 처리된 고춧잎 추출물의 제조 Preparation of Treated Pepper Leaf Extract
(1) 고춧잎 추출물의 제조(1) Preparation of Red Pepper Leaf Extract
본 발명의 고춧잎은 영양지역에서 재배된 PR우뚝 품종을 사용하였다. 건조하여 분쇄한 PR우뚝 품종의 고춧잎 3g에 70%(v/v) 에탄올을 30㎖ 넣고, 상온에서 12시간 동안 진탕하며 추출한 후, 필터하여 동결건조하였다. The pepper leaf of the present invention used the PR tower varieties cultivated in the trophic region. 30 g of 70% (v / v) ethanol was added to 3 g of dried red pepper pulverized varieties of pepper, extracted after shaking for 12 hours at room temperature, and filtered and lyophilized.
(2) 플라즈마 처리된 고춧잎 추출물의 제조(2) Preparation of Plasma Treated Red Pepper Leaf Extract
상기 동결건조한 고춧잎 에탄올 추출물 7g에 증류수 700㎖를 첨가하여 1%(w/v) 용액을 만든 후, 상기 용액을 플라즈마 발생기에 넣고, 0분, 30분, 60분, 90분 및 120분 동안 플라즈마 처리된 고춧잎 추출물을 제조하였다.After adding 700 ml of distilled water to 7 g of the lyophilized red pepper leaf ethanol extract to make a 1% (w / v) solution, the solution was placed in a plasma generator, and plasma was maintained for 0, 30, 60, 90 and 120 minutes. The treated pepper leaf extract was prepared.
본 발명에 사용한 플라즈마는 두 개의 텅스텐 전극 사이에 사인파 펄스형 고전압을 가하여 생성하였으며, 플라즈마 발생기는 도 1에 개시한 바와 같이 전압/고주파 전원장치, 플라즈마 방전부, 처리 테이블의 3 부분으로 구성된다. 플라즈마 방전부는 두께 5mm의 테프론 실드에 지름 3mm, 길이 20mm의 텅스텐 리드를 평행 배치한 후 매립하였다. 220V AC의 전원을 사용하였고, 출력전압은 300V, 전류는 5A로 고정하여 플라즈마를 생성하여 고춧잎 추출물에 처리하였다. The plasma used in the present invention was generated by applying a sinusoidal pulsed high voltage between two tungsten electrodes, and the plasma generator is composed of three parts: a voltage / high frequency power supply, a plasma discharge unit, and a treatment table. The plasma discharge part was embedded in a teflon shield having a thickness of 5 mm by placing a tungsten lead having a diameter of 3 mm and a length of 20 mm in parallel. 220V AC power was used, and the output voltage was fixed at 300V and the current was set at 5A to generate plasma and to process the pepper leaf extract.
실시예Example 1. 총 폴리페놀 함량 및 1. Total polyphenol content and 항산화능Antioxidant activity 측정 Measure
본 발명의 제조방법으로 제조된 플라즈마 처리된 고춧잎 추출물의 총 폴리페놀 함량 및 항산화능을 측정하였다. Total polyphenol content and antioxidant activity of the plasma-treated pepper leaf extract prepared by the preparation method of the present invention were measured.
총 폴리페놀 함량은 표 1에 나타난 바와 같이 120분 동안 플라즈마를 처리하였을 때 증가하는 것을 확인하였고, ABTS 및 DPPH 라디칼 소거능 또한 120분 동안 플라즈마를 처리하였을 때 가장 증가하였다. 이를 통해 120분 동안 플라즈마를 처리한 고춧잎 추출물은 총 폴리페놀 함량 및 항산화능이 향상되는 것을 확인하였다. As shown in Table 1, the total polyphenol content was found to increase when the plasma was treated for 120 minutes, and the ABTS and DPPH radical scavenging ability also increased the most when the plasma was treated for 120 minutes. It was confirmed that the pepper leaf extract treated with plasma for 120 minutes improved the total polyphenol content and antioxidant activity.
(분)Plasma treatment
(minute)
(mg/추출물 1g)Total polyphenol content
(mg / extract 1g)
(conc. 1000㎍/㎖)Radical scavenging ability (%)
(conc. 1000 μg / ml)
실시예Example 2. 세포생존율( 2. Cell survival rate ( cellcell viabilityviability ) 측정) Measure
제조예 1의 플라즈마 처리된 고춧잎 추출물이 세포생존에 미치는 영향을 확인하기 위하여 Mosmann(1983)의 방법을 이용하여 MTT(3-(4,5-dimeth-ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 분석을 실시하였다.In order to confirm the effect of the plasma-treated pepper leaf extract of Preparation Example 1 on the cell survival using the method of Mosmann (1983) MTT (3- (4,5-dimeth-ylthiazol-2-yl) -2,5- diphenyltetrazolium bromide) analysis was performed.
마우스 대식세포주인 RAW 264.7 세포를 100㎕의 DMEM 배지가 담긴 96-웰 플레이트에 1일 동안 배양한 후, 제조예 1의 0~120분 동안 플라즈마가 처리된 고춧잎 추출물 50, 100 또는 200㎍/㎖을 처리하여 24시간 배양하였다. 그 후, 각 웰에 5㎎/㎖의 MTT 용액을 10㎕씩 분주한 후 3시간 동안 배양하면서 환원반응을 유도하였으며, 100㎕의 DMSO(dimethyl sulfoxide) 용액을 첨가하여 보라색의 포르마잔(formazan) 결정을 완전히 용해하였다. 그 후, 분광광도계를 이용하여 570㎚에서 흡광도를 측정하였으며, 고춧잎 추출물 무처리군의 생존율 100%를 기준으로 고춧잎 추출물 처리군의 상대적 세포 생존율을 계산하였다. RAW 264.7 cells, a mouse macrophage line, were cultured in a 96-well plate containing 100 μl of DMEM medium for 1 day, and then 50, 100 or 200 μg / ml of red pepper leaf extract treated with plasma for 0 to 120 minutes of Preparation Example 1. Was incubated for 24 hours. Thereafter, 10 μl of 5 mg / ml MTT solution was dispensed into each well, followed by incubation for 3 hours to induce a reduction reaction, and 100 μl of DMSO (dimethyl sulfoxide) solution was added to form purple formazan (formazan). The crystals were completely dissolved. Thereafter, the absorbance was measured at 570 nm using a spectrophotometer, and the relative cell viability of the pepper leaf extract treatment group was calculated based on the survival rate of 100% of the pepper leaf extract untreated group.
그 결과, 도 2에 나타난 바와 같이 제조예 1의 0~120분 동안 플라즈마가 처리된 고춧잎 추출물은 200㎍/㎖의 농도까지 세포 생존율에 크게 영향을 주지 않은 것으로 보아 세포 독성이 거의 없다는 것을 알 수 있었다.As a result, as shown in FIG. 2, the pepper leaf extract treated with plasma for 0 to 120 minutes of Preparation Example 1 did not significantly affect cell viability up to a concentration of 200 µg / ml, indicating that there was little cytotoxicity. there was.
실시예Example 3. 3. 플라즈마plasma 처리된 고춧잎 추출물의 Of treated red pepper leaf extract NONO (( nitricnitric oxideoxide ) 생성 억제효과) Inhibitory effect on production
항염효과를 검증하기 위해 마우스 대식세포주인 RAW 264.7 세포를 96-웰 플레이트에 1×106cells/㎖가 되도록 접종하고, 37℃ 온도와 5% CO2가 유지되는 배양기에서 24시간 동안 배양하였다. 이후 각 웰에 제조예 1의 0~120분 동안 플라즈마가 처리된 고춧잎 추출물을 1시간 동안 처리하고, 그 후 1㎍/㎖의 LPS를 처리하여 24시간 배양하였다. 배양 후 배양액의 상징액을 얻고, 상징액과 그리스(griess) 시약을 반응시킨 후, 분광광도계를 이용하여 540㎚ 파장에서 흡광도를 측정하였다. NO 생성율은 LPS 처리군 대비 백분율로 나타내었다.To verify the anti-inflammatory effect, RAW 264.7 cells, a mouse macrophage line, were seeded in 96-well plates at 1 × 10 6 cells / ml, and maintained at 37 ° C. and 5% CO 2. The incubator was incubated for 24 hours. Thereafter, each well was treated with pepper leaf extract treated with plasma for 0 to 120 minutes of Preparation Example 1 for 1 hour, and then treated with 1 μg / ml of LPS and incubated for 24 hours. After incubation, the supernatant of the culture was obtained, the supernatant was reacted with a grease reagent, and the absorbance was measured at a wavelength of 540 nm using a spectrophotometer. NO production rate was expressed as a percentage compared to the LPS treated group.
그 결과, 도 2에 나타난 바와 같이 플라즈마를 처리하였을 경우 플라즈마가 처리되지 않은 고춧잎 추출물에 비해 NO 생성이 감소하는 것을 확인할 수 있었고, 플라즈마 처리시간이 길어질수록 NO 생성량의 감소효과가 증가하였다. 이를 통해 본 발명의 플라즈마 처리된 고춧잎 추출물은 항염증용 기능성 소재로 사용 가능하다는 것을 확인하였다. As a result, as shown in Figure 2, when the plasma treatment, it was confirmed that the NO production is reduced compared to the pepper leaf extract not treated the plasma, the longer the plasma treatment time increases the effect of reducing the NO production amount. Through this, it was confirmed that the plasma-treated pepper leaf extract of the present invention can be used as an anti-inflammatory functional material.
Claims (9)
2) 상기 단계 1)의 동결건조된 고춧잎 추출물 1 중량부에 대하여, 80~120 부피부의 물을 첨가한 후 플라즈마를 100분~150분 동안 처리하는 단계;를 포함하는 제조방법에 따라 제조된 고춧잎 추출물 100㎍/ml 또는 200㎍/ml을 유효성분으로 함유하는 염증의 예방 또는 개선용 건강기능식품 조성물.1) adding a solvent to the pepper leaf dry powder to obtain a pepper leaf extract and then lyophilized; And
2) to about 1 part by weight of the lyophilized red pepper leaf extract of step 1), adding 80 to 120 parts by volume of water and then treating the plasma for 100 minutes to 150 minutes; Health functional food composition for the prevention or improvement of inflammation containing red pepper leaf extract 100㎍ / ml or 200㎍ / ml as an active ingredient.
2) 상기 단계 1)의 동결건조된 고춧잎 추출물 1 중량부에 대하여, 80~120 부피부의 물을 첨가한 후 플라즈마를 100분~150분 동안 처리하는 단계;를 포함하는 제조방법에 따라 제조된 고춧잎 추출물 100㎍/ml 또는 200㎍/ml을 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학 조성물.1) adding a solvent to the pepper leaf dry powder to obtain a pepper leaf extract and then lyophilized; And
2) to about 1 part by weight of the lyophilized red pepper leaf extract of step 1), adding 80 to 120 parts by volume of water and then treating the plasma for 100 minutes to 150 minutes; Pharmaceutical composition for the prevention or treatment of inflammatory diseases containing pepper leaf extract 100㎍ / ml or 200㎍ / ml as an active ingredient.
2) 상기 단계 1)의 동결건조된 고춧잎 추출물 1 중량부에 대하여, 80~120 부피부의 물을 첨가한 후 플라즈마를 100분~150분 동안 처리하는 단계;를 포함하는 제조방법에 따라 제조된 고춧잎 추출물 100㎍/ml 또는 200㎍/ml을 유효성분으로 함유하는 피부 염증의 예방 또는 개선용 화장료 조성물.1) adding a solvent to the pepper leaf dry powder to obtain a pepper leaf extract and then lyophilized; And
2) to about 1 part by weight of the lyophilized red pepper leaf extract of step 1), adding 80 to 120 parts by volume of water and then treating the plasma for 100 minutes to 150 minutes; A cosmetic composition for preventing or improving skin inflammation, which comprises red pepper leaf extract 100 µg / ml or 200 µg / ml as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180007220A KR102066845B1 (en) | 2018-01-19 | 2018-01-19 | Plasma-treated pepper leaf extreact with improved anti-inflammatory effect and manufacturing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180007220A KR102066845B1 (en) | 2018-01-19 | 2018-01-19 | Plasma-treated pepper leaf extreact with improved anti-inflammatory effect and manufacturing method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190088752A KR20190088752A (en) | 2019-07-29 |
| KR102066845B1 true KR102066845B1 (en) | 2020-01-16 |
Family
ID=67480831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020180007220A KR102066845B1 (en) | 2018-01-19 | 2018-01-19 | Plasma-treated pepper leaf extreact with improved anti-inflammatory effect and manufacturing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102066845B1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102414267B1 (en) * | 2020-02-20 | 2022-06-29 | 동의대학교 산학협력단 | For antioxidant, antidepressant and antistress compositions comprising citrus unshiu peel extract |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101432940B1 (en) * | 2013-06-12 | 2014-08-21 | 충남대학교산학협력단 | Preparation method of phenol compounds with enhanced physiological functionality by plasma treatment |
-
2018
- 2018-01-19 KR KR1020180007220A patent/KR102066845B1/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101432940B1 (en) * | 2013-06-12 | 2014-08-21 | 충남대학교산학협력단 | Preparation method of phenol compounds with enhanced physiological functionality by plasma treatment |
Non-Patent Citations (3)
| Title |
|---|
| Hend M. Tag., et al. Potential anti-inflammatory effect of lemon and hot pepper extracts on adjuvant-induced arthritis in mice. The J. of Basic & Applied Zoology. 67: 149~157 (2014.10.)* |
| 이종성 외 11명. NF-kappaB 프로모터 활성을 억제하는 식물추출물. 대한화장품학회지. 32(3): 135~140 (2006.09.)* |
| 정경한 외 1명. 플라즈마 처리 phloridzin 반응물의 생리활성 평가. 한국식품저장유통학회지. 24(3): 483~489 (2017.06.30.)* |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190088752A (en) | 2019-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102141080B1 (en) | Composition for skin cell regeneration, anti-wrinkle, anti-imflammation, or skin whitening | |
| KR101611853B1 (en) | Aster glehni fractions or compounds isolated therefrom having anti-inflammatory activity | |
| KR102066845B1 (en) | Plasma-treated pepper leaf extreact with improved anti-inflammatory effect and manufacturing method thereof | |
| KR102138001B1 (en) | Tricholoma matsutake mycellium extract with improved anti-inflammatory effect through plasma treatment and manufacturing method thereof | |
| KR101963628B1 (en) | Anti-inflammatory composition comprising Actinidia arguta stem extract produced by ultra high pressure homogenization as effective component | |
| KR102034178B1 (en) | Plasma-treated pepper leaf extreact with improved skin whitening effect and manufacturing method thereof | |
| KR20140043258A (en) | Novel hemiterpene glucoside compounds isolated from the leaves of spiraea prunifolia and anti-oxidative and anti-inflammatory use thereof | |
| KR102092865B1 (en) | Geumgangsong extract with improved anti-inflammatory effect through plasma treatment and manufacturing method thereof | |
| KR102092872B1 (en) | Composition for anti-inflammation comprising Geumgangsong subcritical water extract as effective component | |
| KR102278649B1 (en) | Anti-inflammatory composition comprising plasma-treated Persimmon tannin as effective component and manufacturing method thereof | |
| KR102016994B1 (en) | Pepper leaf extreact with improved skin whitening effect and manufacturing method thereof | |
| KR20170000366A (en) | Composition for antioxidant, and anti-inflammation effect comprising Cirtus extract and Hylotelephium erythrostictum extract | |
| KR101721666B1 (en) | Skin-whitening compound from Inula britannica, and skin-whitening composition containing the same | |
| KR101963630B1 (en) | Anti-inflammatory composition comprising pepper leaf extract produced by enzyme treatment as effective component | |
| KR101689267B1 (en) | Cosmetic composition for preventing or improving skin wrinkle comprising mixture of red ginseng extract and astaxanthin as effective component | |
| KR101661423B1 (en) | anti-oxidant and anti-inflammation composition extracted from Isodon excisus, and its extracting method | |
| KR20190057658A (en) | An anti-inflammatory or immunological enhancing composition comprising a Halocynthia aurantium tunic fatty acid as an active ingredient | |
| KR102199750B1 (en) | Composition for anti-inflammaion comprising defatted perilla seed extract produced by enzyme treatment as effective component | |
| KR101977869B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
| KR102090181B1 (en) | Anti-inflammatory composition comprising Cacalia firma extract as effective component | |
| KR101988907B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
| KR102002427B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
| KR102093661B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant and anti-imflamation | |
| KR20220152929A (en) | Cosmetic composition for improving atopy comprising angelica tenuissima fermented extracts as an active ingredient | |
| KR102090689B1 (en) | Cosmetic composition containing Oriental Herb Fragrance Active Component alpha-fenchone for Skin Benefit Ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) |